Accessibility links
rheumatoid arthritis rheumatoid arthritis
Stories About

rheumatoid arthritis

Wednesday

A new test could save arthritis patients time, money and pain. But will it be used?

A new precision medicine test could help doctors and patients zero in on the right arthritis drug much sooner. But insurance coverage and drug company incentives are hurdles to widespread use. Adam Gault/SPL/Getty Images hide caption

toggle caption
Adam Gault/SPL/Getty Images

Shots - Health News

A new test could save arthritis patients time, money and pain. But will it be used?

KFF Health News

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

Thursday

Blockbuster drug Humira finally faces lower-cost rivals

AbbVie's Humira was the world's best-selling drug for many years. Now it faces competition for copycats that cost a fraction of its price. David J. Phillip/AP hide caption

toggle caption
David J. Phillip/AP

Shots - Health News

Blockbuster drug Humira finally faces lower-cost rivals

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

Blockbuster drug Humira finally faces lower-cost rivals

Listen · 3:51
  • Download
  • <iframe src="https://www.npr.org/player/embed/1188745297/1188780602" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Monday

Why Hoarding Of Hydroxychloroquine Needs To Stop

Transmission electron micrograph of particles of SARS-CoV-2 — the coronavirus that causes COVID-19. NIAID/Flickr hide caption

toggle caption
NIAID/Flickr

Shots - Health News

Why Hoarding Of Hydroxychloroquine Needs To Stop

WBUR

Despite Trump's public remarks, infectious disease experts say it's premature to think hydroxychloroquine will help against COVID-19. And patients with lupus or rheumatoid arthritis rely on the drug.

Why Hoarding Of Hydroxychloroquine Needs To Stop

Listen · 4:16
Transcript
  • Download
  • <iframe src="https://www.npr.org/player/embed/820228658/820293513" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Monday

FDA-Approved Knock-Offs Of Biotech Drugs Could Safely Save Big Bucks

In 2015, the Sandoz unit of drugmaker Novartis won Food and Drug Administration approval of a drug called Zarxio, which is similar to Amgen's Neupogen, a medicine that boosts the production of white blood cells. Sebastien Bozon/AFP/Getty Images hide caption

toggle caption
Sebastien Bozon/AFP/Getty Images

Shots - Health News

FDA-Approved Knock-Offs Of Biotech Drugs Could Safely Save Big Bucks

Drugs that consist of proteins and antibodies typically made by living organisms represent the new frontier in drug industry competition.

Wednesday